UK Markets open in 3 hrs 13 mins

Galapagos NV (GLPGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
74.270.00 (0.00%)
At close: 9:54AM EDT
Sign in to post a message.
  • N
    NV
    This stock is coming into buying territory any time now. Accumulation has been going on for quite some time. Awaiting confirmation
  • D
    Didier
    Quite the day. If anyone wonders what a real institution (Blackrock) selling looks like, this was it. Hard to be positive about it, but at least buyers started stepping up at 74 usd, I took the chance to add some as well. Glad the 2017 support levels are holding for now.
    Now, when it comes to the ER.. I don't think the financials need much of an explanation, the small "profit" was mainly due to the Fidelta sale and EUR/USD exchange literally hitting its low at the end of March. Sales and royalty income was rather low, and today during the presentation they said France would also need Manta results before allowing Filgo for men. Management doesn't worry about the outcome of the study, but it doesn't really reinstate the confidence from the investors. Hopefully, Manta will be just fine and sales will follow slowly but surely (obviously they still need to fix reimbursements, but investors are impatient).
    Dropping the trash/filler from their pipeline is a good move in my opinion, but it's easy to see all the things dropped as a waste of money and just another failure. But focusing on just a couple of areas, where they should have plenty of expertise, will be beneficial in the long run. They dropped '1205 in IPF because they felt it was a molecule that would be suited for combination with another drug, not as a "stand-alone", while the chitinase inhibitor showed more promise. Metabolic diseases were dropped because of the "difficulty level", I think it would take too many resources that are better spent in their core area.
    As I mentioned here yesterday, the potential for SIK inhibitors (Toledo) is huge.. But being first means it's also risky and difficult. For the people who like to read, there is some studies to be found online. The analyst from Jefferies stated that a succesful Toledo molecule would reach peak sales of 3b, which is obviously a bit random, since it's so early and PoC studies are still underway with first results only expected this summer..
    Anyway, during the webcast there was another confirmation that they are looking to "fill the gap" between Filgo and the existing pipeline. Both acquiring a late-stage ph2 molecule (together with Gilead?) and getting the commercial rights for the European sales of a product are being looked at. Getting in some revenue instead of sitting on all that cash would be a good move, as long as they are patient while looking for a target and don't overpay or rush things.
    There is some things to look forward to, but all in all I expect a calm year. Hopefully when it comes to share price, we will also find a bottom soon, although cheap shares are also an interesting prospect.
    Personal: Obviously I'm long this stock. In an overpriced market I thought this was an interesting target, because of the cash, the potential and the belief that this is way oversold because it did not live up to the hype. Also, got a biochemistry background which helps. Pretty active here because I'm still building a position since, you know, the catching a falling knife thing. Now, I do not set price targets, because I intend to let this compound for the rest of my life (I'm in my twenties).
    Sorry for the novel, but this board really needs some positives. (I understand the pain if you are sitting on 100+ euro shares..)
  • J
    Julius Caesar - Renaissance
    There are some technical indicators crosses that could push for a major sell off in this stock.
    On another side those who like high risk - medium reward a swing from 61-63 to high 68 could be made.
    Know: it is high risk, because certain lines are crossed that could cause a major sell off.
  • P
    PriceItRight
    One day this will run, it already had 4 major cuts in price and now it is flat.
  • T
    TW
    Somebody appears determined to sell into any strength.
  • I
    Ingmar
    This stock has been beaten down so much. And also for a good reason. one of their products totally failed. However it's been beaten down to much. The rest of their pipeline still looks promising. So I'm bullish. this stock will have a strong rebound in 2022
  • T
    TW
    Immediate sellling into strength. Some people, unfortunately, still want out at any price and I don't think they're all retail. Otherwise, nothing wrong with the ER in relation to expectations.
  • P
    PriceItRight
    Buy rating and PT 110#$%$ at Deutsche Bank
  • A
    A
    quiet here you all must be adding.
  • P
    PriceItRight
    consolidation period is over, nice push up, volume is everything and it is high, so it means change of trend direction.
  • J
    Julius Caesar - Renaissance
    54-56 euro is likely going to be the next areas of support for this titanic
  • A
    A
    maybe its not so bad that the cso is leaving

    shake things up a bit!
  • K
    Kevin
    Cant wait to get out of this stock
  • T
    TW
    Looks like the market is giving the thumbs down to the AGM.
  • M
    Marie
    Trading below cash, has a whole bunch of programs/partnerships,

    UC a huge market

    Add now below 80, in time $100+
  • T
    TW
    A case of buy the rumor sell the fact, no doubt, but that Japan news seems more valuable to me than the market is pricing in. General market jitters perhaps weighing on the price?
  • D
    Didier
    No idea where the incredibly weak hands keep coming from, but I'm not selling and neither is Gilead.
  • V
    ValueForAll
    $GLPG , please stay on low-mid 80s at least for a couple more weeks. I need to accumulate more cash to buy at this ridiculous price level.
  • F
    Frank B
    Capital increases its holdings over the 5% threshold. Filed.